MWA Asset Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.57M Buy
18,170
+256
+1% +$55.1K 2.07% 14
2026
Q1
$3.9M Buy
17,914
+507
+3% +$112K 2.13% 15
2025
Q4
$3.98M Sell
17,407
-479
-3% -$109K 2.22% 13
2025
Q3
$4.14M Buy
17,886
+601
+3% +$122K 2.29% 11
2025
Q2
$3.21M Buy
17,285
+195
+1% +$36.2K 1.96% 14
2025
Q1
$3.58M Buy
17,090
+285
+2% +$55.4K 2.48% 10
2024
Q4
$2.99M Buy
16,805
+229
+1% +$42.1K 1.99% 13
2024
Q3
$3.27M Buy
16,576
+42
+0.3% +$7.84K 2.18% 11
2024
Q2
$2.84M Buy
16,534
+261
+2% +$43.2K 2.02% 11
2024
Q1
$2.96M Buy
16,273
+657
+4% +$113K 2.15% 12
2023
Q4
$2.42M Buy
15,616
+890
+6% +$130K 2% 12
2023
Q3
$2.2M Buy
+14,726
New +$2.16M 2.12% 13

Other funds holding ABBV

MWA Asset Management's ABBV Position: Q2 2026 in Review

MWA Asset Management increased its AbbVie (ABBV) stake by 1.4% in Q2 2026, buying an estimated $55.1K and bringing the position to 18,170 shares worth $4.57M. The position accounts for 2.07% of the portfolio, ranked #14.

MWA Asset Management first reported a position in ABBV in Q3 2023 and has held it in 12 quarters since. 4,194 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • MWA Asset Management held 18,170 shares of AbbVie worth $4.57M as of Q2 2026.
  • MWA Asset Management bought 256 AbbVie shares in Q2 2026, an estimated $55.1K.
  • AbbVie made up 2.07% of MWA Asset Management's portfolio in Q2 2026, its #14 holding.
  • MWA Asset Management first reported a position in AbbVie in Q3 2023 and has held it in 12 quarters since.
  • 4,194 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on MWA Asset Management's 13F filing for Q2 2026, filed 31 Jul 2026.